Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Trump Presidency -- Ignore unavailable to you. Want to Upgrade?

To: i-node who wrote (164504)	5/18/2020 12:50:44 AM
From: Sam	3 Recommendations Recommended By bentway CentralParkRanger Ms. Baby Boomer Read Replies (2) \| Respond to of 357196

Yet another study shows hydroxychloroquine doesn't work against Covid-19 By Elizabeth Cohen, Senior Medical Correspondent Updated 4:57 PM ET, Mon May 11, 2020 (CNN)A new study -- the largest of its kind -- shows that hydroxychloroquine, the drug touted by President Trump, does not work against Covid-19 and could cause heart problems. The study was published Monday in the Journal of the American Medical Association. It follows a study published Thursday in the New England Journal of Medicine that also showed the drug doesn't fight the virus. Even before these reports were published, the US Food and Drug Administration and the National Institutes of Health issued warnings about using the drugs for coronavirus patients. "The nail has virtually been put in the coffin of hydroxychloroquine," said Dr. William Schaffner, an infectious disease expert and longtime adviser to the US Centers for Disease Control and Prevention. continues at cnn.com

To: i-node who wrote (164504)	5/18/2020 12:54:46 AM
From: Sam	Read Replies (1) \| Respond to of 357196

Every hypothesis can be proven true if you just ignore any trials that don't verify it. You keep repeating the same line over and over again. It makes you seem to be OCD. Studies find further lack of COVID benefit from hydroxychloroquine Filed Under: COVID-19 Chris Dall \| News Reporter \| CIDRAP News May 15, 2020 Center for Infectious Disease Research and Policy Results from two new studies, including the first randomized controlled trial, are providing further evidence that the antimalaria drug hydroxychloroquine may not help COVID-19 patients. The two studies, published yesterday in BMJ, found that, when compared with standard treatment, the use of hydroxychloroquine did not increase the likelihood of virus elimination in Chinese patients with mild-to-moderate COVID-19, nor did it have any effect on reducing admissions to intensive care or death in French patients with more severe illness. Both studies also found a higher rate of adverse events in patients treated with the drug. The authors of both papers conclude that the results do not support the continued use hydroxychloroquine in these patients. Randomized trial resultsIn the first study, investigators in China randomized patients treated at 16 government-designated COVID-19 treatment centers to receive either standard-of-care treatment (the control group) or standard-of-care plus hydroxychloroquine (the treatment group) on a 1:1 basis. Patients in the treatment group were given hydroxychloroquine within 24 hours of randomization. A total of 150 patients were randomized from Feb 11 to Feb 29 (75 in the treatment group and 75 in the control group), and nearly all had mild-to-moderate illness, with only two patients having severe disease on screening. The primary outcome of the study was whether patients had negative conversion of SARS-CoV-2—elimination of the virus that causes COVID-19—by 28 days. The investigators had also planned to look at clinical improvement in patients with severe disease, but because the trial was stopped early because of a lack of eligible patients and only two patients were severely ill, they did not present those results. Among the 150 patients, the mean duration from onset of symptoms to randomization was 16.6 days. A total of 109 patients (53 in the treatment group and 56 in the control group) had negative conversion well before 28 days, and 41 patients (22 in the treatment group and 19 in the control group) did not reach negative conversion. Overall, the probability of negative conversion of SARS-CoV-2 by 28 days in the treatment group was 85.4% (95% confidence interval [CI], 73.8% to 93.8%), compared with 81.3% in the control group (95% CI, 71.2% to 89.6%), for an absolute difference of 4.1 percentage point (95% CI, -10.3 to 18.5). The median time to virus elimination was also similar in the treatment group (8 days; 95% CI, 5 to 10 days) compared with the control group (7 days; 95% CI, 5 to 8 days). And the probability of alleviation of symptoms by 28 days was also similar (59.9% in the treatment group vs 66.6% in the control group). But the safety analysis found that 30% of the patients treated with hydroxychloroquine reported adverse events, compared with only 9% of the patients who received standard-of-care treatment. "Data from our trial do not provide evidence to support the use of hydroxychloroquine in this population, particularly considering the increased adverse events," the authors wrote. But they noted that further research is needed on the use of the drug at an earlier stage of the disease, preferably within 48 hours of symptom onset. continues at cidrap.umn.edu

To: i-node who wrote (164504)	5/18/2020 8:27:37 AM
From: Brumar89	Respond to of 357196

Why hasn't Trump's miracle cure worked for vets? The VA can sacrifice them at Trump's discretion and its okay with you Trumpsters with your blind faith in Lord Trump.. You mention Zelenko, despite us not knowing how many, if any, of his patients had covid. He doesn't do tests, he does telemedicine and diagnoses based on "clinical" symptoms.